News
Ending a 20-year-plus drought, Merck & Co.’s Keytruda demonstrated that its use around surgery can reduce the risk of certain ...
4h
Stockhead on MSNHealth Check: Biotechs recover as peace descends on the FDA – for nowGlobal and US biotech shares have recovered from their lows on signs that the chaos created by the Trump administration is ...
Gilead Sciences said on Monday a late-stage study showed that its drug Trodelvy used in combination with Merck's ...
6d
GlobalData on MSNMSD reports outcomes from Keytruda combination trial for head and neck cancerThe drug's safety profile was consistent with that found in prior studies, with no new safety signals identified.
The new facility will produce biologic drugs and Keytruda, becoming Merck’s first in-house US site to make the blockbuster ...
Akeso has shared for the first time overall survival data from a high-profile Keytruda head-to-head trial for its PD-1xVEGF ...
Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or ...
The FDA is currently reviewing Merck’s sBLA for Keytruda in head and neck cancer, with a target action date of June 23.
The Delaware facility will ensure a domestic supply of biologic drugs including the cancer drug Keytruda.
In advanced head and neck squamous cell carcinoma, evorpacept and Keytruda didn’t meet the primary endpoints of the ASPEN-03 ...
While drugmakers battle over costs, MoveSmarter Health, a U.S. startup launched in Argentina, is sidestepping the fray with a ...
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results